In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Comes First In FDA Land, Excessive Claims Finding Or Facility Inspection?

This article was originally published in The Rose Sheet

Executive Summary

Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' manufacturing facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections – further reason for companies to keep their claims in check.


Related Content

‘Ant-type Insects’ And Expired Ingredients: FDA Warns Bioque Following Inspection
FDA Warning Letter Depicts Personal-Care Regulation's Present, Possible Future
FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims
FDA Warns Reviva Labs For Collagen-Building, Anti-Inflammatory Claims
FDA Warning Cites Ageless Derma's Anti-Wrinkle, Brightening Claims
FDA Cites Adulteration In Warning Letter To Juice Beauty Manufacturer
FDA Warning To L’Oreal Creates Uncertainty For Anti-Redness, Dark Spot Treatments
Rash Of FDA Warning Letters Raises Questions For Cosmetics Industry





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts